Filaggrin haploinsufficiency is highly penetrant and is associated with increased severity of eczema: further delineation of the skin phenotype in a prospective epidemiological study of 792 school children.
BACKGROUND
Null mutations within the filaggrin gene (FLG) cause ichthyosis vulgaris and are associated with atopic eczema. However, the dermatological features of filaggrin haploinsufficiency have not been clearly defined.


OBJECTIVE
This study investigated the genotype-phenotype association between detailed skin phenotype and FLG genotype data in a population-based cohort of children.


METHODS
Children (n = 792) aged 7-9 years were examined by a dermatologist. Features of ichthyosis vulgaris, atopic eczema and xerosis were recorded and eczema severity graded using the Three Item Severity score. Each child was genotyped for the six most prevalent FLG null mutations (R501X, 2282del4, R2447X, S3247X, 3702delG, 3673delC). Fisher's exact test was used to compare genotype frequencies in phenotype groups; logistic regression analysis was used to estimate odds ratios and penetrance of the FLG null genotype and a permutation test performed to investigate eczema severity in different genotype groups.


RESULTS
Ten children in this cohort had ichthyosis vulgaris, of whom five had mild-moderate eczema. The penetrance of FLG null mutations with respect to flexural eczema was 55.6% in individuals with two mutations, 16.3% in individuals with one mutation and 14.2% in wild-type individuals. Summating skin features known to be associated with FLG null mutations (ichthyosis, keratosis pilaris, palmar hyperlinearity and flexural eczema) showed a penetrance of 100% in children with two FLG mutations, 87.8% in children with one FLG mutation and 46.5% in wild-type individuals (P < 0.0001, Fisher exact test). FLG null mutations were associated with more severe eczema (P = 0.0042) but the mean difference was only 1-2 points in severity score. Three distinct patterns of palmar hyperlinearity were observed and these are reported for the first time.


CONCLUSIONS
Filaggrin haploinsufficiency appears to be highly penetrant when all relevant skin features are included in the analysis. FLG null mutations are associated with more severe eczema, but the effect size is small in a population setting.
Brown
S J
SJ
Department of Dermatology, Royal Victoria Infirmary, Newcastle upon Tyne, UK. sara.brown@ncl.ac.uk
Relton
C L
CL
Liao
H
H
Zhao
Y
Y
Sandilands
A
A
McLean
W H I
WH
Cordell
H J
HJ
Reynolds
N J
NJ
D002648:Child; D003876:Dermatitis, Atopic / Q000235:genetics; D004485:Eczema / Q000235:genetics* / Q000473:pathology; D005260:Female; D000091344:Filaggrin Proteins; D020022:Genetic Predisposition to Disease / Q000235:genetics; D006801:Humans; D016112:Ichthyosis Vulgaris / Q000235:genetics; D007381:Intermediate Filament Proteins / Q000235:genetics*; D008297:Male; D009154:Mutation / Q000235:genetics*; D019683:Penetrance; D010641:Phenotype; D011446:Prospective Studies; D012720:Severity of Illness Index
C000717249:FLG protein, human; D000091344:Filaggrin Proteins; D007381:Intermediate Filament Proteins
J Invest Dermatol. 2009 Mar;129(3):543-52
19209157
J Allergy Clin Immunol. 2004 May;113(5):832-6
15131563
J Invest Dermatol. 2008 Jul;128(7):1669-75
18239616
J Invest Dermatol. 2009 Apr;129(4):1042-5
18987673
J Invest Dermatol. 2007 Jul;127(7):1667-72
17301831
Nat Rev Mol Cell Biol. 2005 Apr;6(4):328-40
15803139
Pharmacogenomics. 2008 Apr;9(4):399-413
18384254
Mol Cell Biol. 1993 Jan;13(1):613-25
8417356
J Invest Dermatol. 2007 Mar;127(3):564-7
16990802
Dermatol Ther. 2004;17 Suppl 1:43-8
14728698
J Invest Dermatol. 2008 Jun;128(6):1430-5
18049447
Br J Dermatol. 1985 Jun;112(6):679-85
4005167
Nat Genet. 2006 Apr;38(4):441-6
16550169
J Invest Dermatol. 2005 May;124(5):1071-4
15854050
J Allergy Clin Immunol. 2007 Jul;120(1):150-5
17512043
J Invest Dermatol. 2006 Aug;126(8):1770-5
16810297
J Cell Biol. 2007 Apr 9;177(1):173-82
17403930
Acta Derm Venereol. 1999 Sep;79(5):356-9
10494710
Acta Derm Venereol. 2007;87(6):499-505
17989887
J Invest Dermatol. 2008 Aug;128(8):2117-9
18305568
Nat Cell Biol. 2007 Jun;9(6):666-74
17515931
J Allergy Clin Immunol. 2008 May;121(5):1203-1209.e1
18396323
Nat Genet. 2006 Mar;38(3):337-42
16444271
Br Med J. 1966 Apr 16;1(5493):947-50
20790920
J Allergy Clin Immunol. 2008 Oct;122(4):689-693
18774165
Nat Genet. 2007 May;39(5):650-4
17417636
Exp Dermatol. 2005 Oct;14(10):719-26
16176279
Nat Genet. 2005 Jan;37(1):56-65
15619623
J Allergy Clin Immunol. 2008 Apr;121(4):872-7.e9
18325573
Br J Dermatol. 2007 Oct;157(4):645-8
17714568
Arch Dermatol Res. 2005 Dec;297(6):235-41
16261374
J Cell Biol. 2003 Nov 24;163(4):901-10
14638864
Hum Mol Genet. 2005 Jan 15;14(2):335-46
15590704
Curr Opin Allergy Clin Immunol. 2008 Oct;8(5):406-10
18769192
J Allergy Clin Immunol. 2008 Apr;121(4):940-46.e3
18313126
J Invest Dermatol. 2008 Jun;128(6):1591-4
18094728
J Allergy Clin Immunol. 2008 May;121(5):1294-5; author reply 1295-6
18395783
J Invest Dermatol. 2008 Jun;128(6):1436-41
18200065